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SUMMARY 
The present study reports results pertaining to an "open trial" with long acting haloperidol decano.iie 
injections in the maintenance therapy of schizophrenic patients satisfying DSM-III criteria. 33 patients 
suffering from schizophrenia entered the trial and were put or long acting haloperidol decanoate injections. 
The follow-up period was 6 months and the condition of the patients was monitored every 4 weeks. 30 pat-
ients completed the trial. The results of study indicate haloperidcl decanoate to be an effective agent in tic 
maintenance therapy of ambulatory schizophrenic patients. During the period of follow-up 
significant rcductiur ir manifest psvchopathologv was observed. Most of the patients were better 
offat the end of the trial. None of the patients showed deterioration during the study period. Side effects 
were few, the number of patients experiencing them was small and these side effects improved with passage of 
time. 
Maintenance drug therapy is an 
important aspect of the treatment pro-
gram/a: of pttients witlt schizophrenia. 
It has been reported by Richards et al. 
(1982) that a substantial number of schi-
zophrenic p.Uieuts ate cither irregular in 
talcing prescribed medicalior or disconti-
nue therapy of their own accord. In 
this respsct, availability of long acting or 
depot preparations of antipsychotics 
offer considerable advantages. 
Haloperidol is one of the jnost widely 
prescribed, highly effective and well esta-
blished antipsychotics (Frcyhan, 1980; 
Ayd, 1978). Introduction of Haloperidol 
decanoate, which is a long acting depot 
neuroleptic, has added a new dimension 
to the maintenance therapy of schizo-
phrenic disorders. Efficacy and safety 
of haloperidol decanoate has been docu-
mented in in my studies (Arap Mengech 
& Wa/ome, 1934; Youssof, 1982; Roose, 
1982; Richards et al.. 1982; GeUcretal., 
1982; Zissisct al., 1982). 
Tne d'"ng trial Was undertaken with 
the aims of assessing the efficacy and 
safety of haloperidol in the maintenance 
drug therapy of ambulatory/non-hospi-
talized schizophrenic patients. 
Material and Methods 
The study was conducted at the De-
partment of Psychiatry, Postgraduate Ins-
titute of Medical Education & Research. 
Chandigarh. The Department of Psychi-
atry runs an active outpatient clinic and 
also has a 24 bedded acute admission 
unit. The department does not havi 
any chronic or long stay psychiatric beds. 
Selection Criteria 
Ambulatory schizophrenic patients oi 
cither sex receiving maintenance therapy 
from the outpatient clinic of the depart-
ment were screened. Patients who satis-
fied DSM-III (APA, 1980) criteria for the 
diagnosis of schizophrenia and who were 
receiving maintcnace therapy either in 
the form of depot preparation of fluphe-
nazine decanoate or oral neuroleptics 
were taken up for the study. Patients 
1. Professor arid Head > Department of Psychiatry, Postgraduate Institute of Medical Education and 
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below the age of 16 years or above the 
age of 55 years were excluded. Acutely 
disturbed patients who were otherwise 
not on maintenance drug therapy were 
also excluded. Pregnant women and 
pitients with gross neurological or major 
physical disorders were also excluded. 
Assessments 
At the commencement of the study, 
patients were interviewed using a struc-
tured clinical interview schedule. On 
ill: basis of the clinical interview, the 
patients were rated on the following : 
(a) The Brief Piychiatric Rating 
Scale-BPRS (Overall & Gorham, 
1962). 
(b) The Scale for the Assessment of 
Negative Symptoms-SANS 
(Andreasen, 1984). 
(c) Clinical Global Impression Scale. 
An eighteen item version of BPRS 
I Overall & Gorham, 1962) was used to 
obtain ratings on manifest psychopatho-
'"gy. SANS (Andreasen, 1984) was 
employed to assess the severity of negative 
symptoms. This scale is divided into 
5 subsections : affective flattening, alogia, 
avolition-apathy, anhedonia-asociality 
and attentional impairment. The seve-
rity of the illness and improvement during 
the period of drug trial was assessed on 
clinical global impressior scale. 
In addition to these instruments which 
assessed clinical status of the patierts, 
following scales were used to monitor 
unwarranted side effects attributable to 
the drug therapy : 
(a) Abnormal Involuntary Move-
ment Scale (Guy, 1976). 
(b) Dosage Record and Treatment 
Emergent Symptom Scale 
(DOTES). 
(c) Extrapyramidal Symptom Rating 
Scale. 
Assessment and Drug Dosage Schedule; 
For maintenance therapy, haloperi-
dol decanoate injections were admui's-
tered as follows : 
depending on the severity of mani-
fest psychopathology, the patients were 
labelled as having mild, moderate or 
severe psychopathology. 
For mild symptology, the patients were 
given 50-100 mg of haloperidol decano-
ate at 4 weekly interval. For moderate 
severity of psydioparhology, patients were 
given 150-200 mg haloperidol once every 
4 weeks and for severe psychopathology, 
haloperidol decorioat'j in the dose range 
of 250-300 mg at 4 weekly interval was 
prescribed. 
Since at the commencement of the 
study, all of the patients were receiving 
maintenance drug therapy (other than 
haloperidol decanoate), the daily dose of 
existing neuroleptic was converted to mg. 
equivalent dose of haloperidol decanoate 
injections. Injections of haloperidol 
decanoate were administered through 
intramuscular route once every 4 weeks. 
The patients were maintained on these 
injections for 24 weeks. Benzodiazepines 
for night sedation were prescribed as ard 
when recessary. For extrapyramidal 
side effects, Benzhexol in appropriate 
doses was also p-escribed. 
During the period of follow-up, the 
patients were reassessed on the assessment 
scales mentioned earlier. After the 
commencement of long acting haloperi-
dol decanoate, the first two assessments 
were carried out at 2 weeks interval. After 
that, the patients were assessed once 
every 4 weeks. Thus every patients was 
assessed on 8 occasions at week 0, 2,4,8, 
12,16,20 and 24. 
Routire urine analysis was performed 
at the beginning and the end of the trial. 
Complete haemogramme, serum crea-
tine, b'lirubin ard cholesterol estima-
tions were also dore at the start and end 
of the trial period, 146  V. K. VARMA AND P. KULHARA 
Informed consent was obtained from 
each patient and /or a key relative looking 
after the patient before including any 
patient in the trial. 
For data analysis paired V test was 
employed. 
Results 
33 patients who satisfied DSM-III 
(APA, 1980) criteria for the diagnosis 
of schizophrenia entered the trial. All 
these patients were receiving maintenance 
drug therapy from the outpatient clinic. 
3 patients discontinued the treatment and 
did not come for follow-i'p assessments. 
30 patients were maintained on injectiors 
of halopendol decanoate and completed 
the trial period of 24 weeks. 
The study sample consisted of 15 
males and 15 females. The mean age 
of the entire cohort was 30.6 years fSD 
7.66 years) and the age range was from 
17 years to 50 years. 
Subtyping of schizophrenia according to 
DSM-III was done and 11 patients were 
subtyped as paranoid, 13 as urdifferen-
tiated and 6 as residual subtyoe. As 
regards the duration of illness prior to 
inclusion in the study, 9 patierts had 
been ill for 3 years, 5 had been ill for 4 to 
5 years, 10 for 6-10 years and 6 patierts 
had been ill for more than 10 years. 
All of the trial entrants were on neuro-
leptic msdication. 16 patients were do-
ing well on treatment but 14 were not 
maintaining a satisfactory level of func-
tioning. 21 patients were also receiving 
a benzodiazepine preparation and 25 
patients were on antiparkinsonian agert. 
Laboratory findings like total haemo-
gramms, urine analyst?, serum bilirubin, 
serum cholesterol, serum creatinine and 
random blood sugar were within normal 
range for trial entrants at the start as 
well as at the end of the trial. 
Severity of the illness on clinical exa-
mination was assessed at the time of intake 
and was repeatedly reassessed during the 
priqd of follow-up. For the entire cohort, 
the mean score on severity of illness at the 
time of intake was 4.35 (S.D-=0.60) 
which came down to 3.63 (S.D.=0.71) 
at the time of the final assessment at 24th 
week. On applying pai
red V test, this 
change was found to be significant (t= 
5.86, p<0.001). Significant reduction in 
the severity of illness score was first obser-
ved at 8th week and this trend was main-
tained all through the trial period. These 
findings are displayed in table 1. These 
results suggests that long acting injection 
of haloperidol decanoate is effective in 
the maintenance therapy of ambulatory 
schizophrenic patients. 
As regards global clinical improve-
ment, 2 weeks after the commencement 
of the trial i.e. 2 weeks after the first injec-
ion of haloperidol decanoate, 13 patients 
were assessed to have minimal improve-
ment, 12 patients did not display any 
change and 5 patients could not be assessed. 
By the 4th week, global improvement was 
in evidence and this trend continued all 
through the trial period. At the end of 
the study period, 20 patients had shown 
much improvement and 10 had minimally 
improved. It is noteworthy that none of 
the patients displayed deterioration while 
on maintenance therapy with haloperidol 
decanoate injection. Because of small 
number of patients in each categoty, non-
parametric statistical test of significance 
were not applied. However, paired 't' 
test was utilized to assess statistical signi-
ficance of the difference between mean 
global improvement score at week 2 with 
that of subsequent weeks and at week 24. 
These comparisons brought out signifi-
cant differencesirdicating global improve-
ment at the end of the trial. These results 
are shown in Table 1. 
Manifest psychopathology was asse-
ssed by employing the Brief Psychiatric 
Rating Scale-BPRS (Overall & Gorham, T
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1962). The mean BPRS score for the 
entire cohort at the time of intake was 
35.45 (S.D. =6.611. This gradually de-
clined over the study period and by the 
time of final assessmert at 24th week it 
was found to be 26.43 (S.D. = 5.281. This 
indicates significant reduction (paired 
V test, t=9.36, p< 0.001). It is worth 
emphasisirg that significant reduction in 
mean BPRS score was observed at 2nd 
week and this redaction continued all 
through the trial period (Table 2). 
Tne effect of ha'operidol decanoate 
on "negative symptoms" as assessed on. 
the Scale for the Assessment of Negative 
Symptoms—SANS (Andrcasen, 1984) 
was also evaluated. These results are 
depicted in table 3. It can be seen that 
haloperidol decanoate brought about 
significant reduction in total SANS score 
(of mean SANS score 57.78, S.D. = 16.37 
at intake with mean SANS score of 40.10, 
S.D.= 16.68 at the termination of trial; 
t=5.14, p<0.001). Haloperidol decano-
ate was also observed to exert ameliora-
ting effect on negative symptoms comp-
lexes of affective flattening, avolition-
apathy and anhedonia fTable 3). 
Through out the duration of follow-
up, side effects were closely monitored. 
As stated earlier, to achieve this objective, 
3 different kinds of instruments were used 
namely the Abnormal Movement Scale, 
Extrapyramidal Symptom Rating Scale 
and the Dosage Record and Treatment 
Emergent Symptoms Scale. Or the 
basis of assessments on all these three 
scales, a composite rating of side effects 
was attempted and the patients were 
assigned to any one of the following cate-
gories : (i) no sigrificant side effects, 
(ii) side effects present but do not signi-
ficantly interfere with the functioning of 
the patients (iii) significant impairment 
in the functioning of the patients due to 
side effects and (iv) side effects nullify 
therapeutic effects. 
15 patients were rated to have abnor-
mal involuntary movements on AIMS 
(Guy, 1976) at the commencement of the 
trial and these were observed to persist 
all through the period of the trial. How-
ever, in none of the patients they were 
thought to outweigh therapeutic effects 
of haloperidol decanoate. Also, these 
abnormal movemerts were not perceived 
by the patients to cause significant impair-
ment in their functioning. If anything, 
the mean composite side effects score 
gradually declined over the duration of 
the trial and was observed to have come 
down from an initial score of 3.92 (S.D.= 
2.28) to 2.10 (S.D.= 1.62) (t=2.59, 
p<0.05). This result is shown in table 4. 
The global assessment of parkinso-
nian side effects on Extrapyramidal Symp-
tom Ratirg Scale also remained unchan-
ged through out the duration of the trial 
period (mean rating of 1.08 (S.D.=0.64) 
at 2rd week and 0.94 (S.D.=0.25) at 
24th week, (t=1.13, p<0.05). 3 patients 
had akathesia of mild nature which was 
transient. 6 patients had tremors of 
m'ld natu
re and two patients developed 
tremors during the period of trial. How-
ever, ir none of the patients, tremors 
interefered significantly with their func-
tioning. 4 patients displayed rigidity 
at the commencement of the trial and in 
7 patients rigidity emerged as a new symp-
tom during the trial. Lack of facial expre-
ssion was common which 22 patients had 
to begin with and 3 patients were added 
to this number as they had developed 
this symptom later on. Rest of the extra-
pyramidal symptoms were uncommon. 
Discussion 
This open drug trial with haloperi-
dol decanoate, though compromized to 
a certain extent because of short dura-
tion of follow-up and small size of the 
sample, nonetheless demonstrates that 
long acting injection of haloperidol is 150  V. K. VARMA AND P. KULHARA 
an efficient agent in the maintenance 
therapy of ambulatory schizophrenics. 
The study also shows that nearly all of jhe 
patients included in the trial were doing 
reasonably well on intra-muscular halo-
peridol decanoate administered orce 
every 4 weeks. More significantly, not 
even a single patient deteriorated dur-
ing the period of follow-up whilst on 
haloperidol decanoate. It is also appa-
rent from the present stvdy that halo-
peridol decanoate can be successfully 
used as a maintcnarce agent for patients 
miintained on other neuroleptic medi-
cation. In this respect our findings arc 
in agreement with the fit 1 dings of Richards 
etal. (1982), Geldcrs ct al. (1982), Yous-
sef (1982) and Roosc (1983). 
In our study, haloperidol decanoate 
was fourd to be safe as far as production 
of side effects is concerned. Side effects 
emerging durirg the treatment were few 
ard transient. Serious side effects were 
not encountered- Thus, it would appear 
that the lonp acting injections of halo-
peridol were we'l tolerated. 
An additional advantage of halo-
peridol injection would appear to be its 
ability to combat "negative symptoms." 
Other drug trials with this preparation 
are somewhat silent on this point but 
results of the present work, where an 
established scale for the assessment of 
negative symptoms was employed, show 
that haloperidol decanoate leads to subs-
tantial improvement in negative symp-
toms. 
To conclude, it can be summarized 
that introduction of haloperidol decano-
ate is a significart and beneficial addi-
tion to existing modalities of treatment for 
maintenance therapy of schizophrenia. 
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